Depression and Vitamin D: A Peculiar Relationship

Nisha Saji Parel 1, Parimi Vamsi Krishna 2, Anuradha Gupta 3, Kamsika Uthayaseelan 4, Kivonika Uthayaseelan 5, Monika Kadari 6, Muhammad Subhnan 7, Sripada Preetham Kasire 8

1. Family Medicine, Tbilisi State Medical University, Tbilisi, GEO 2. Internal Medicine, Jagadguru Jayadeva Murugarajendra Medical College, Davangere, IND 3. Research, Government Medical College Nagpur, Nagpur, IND 4. Internal Medicine, All Saints University College of Medicine, Saint Vincent and the Grenadines, Kingstown, VCT 5. Internal Medicine, All Saints University School of Medicine, Dominica, Roseau, DMA 6. Internal Medicine, Bhaskar Medical College, Hyderabad, IND 7. Internal Medicine, Jinnah Hospital, Lahore - Allama Iqbal Medical College, Lahore, PAK 8. Internal Medicine, Mamata Medical College, Hyderabad, IND

Corresponding author: Nisha Saji Parel, nishaparel@gmail.com

Abstract

Depression is a psychiatric disorder characterized by various symptoms that can impact one's quality of life. Vitamin D, a fat-soluble vitamin, is well-known for its role in bone health, and research on its effects on mental health has only recently emerged. Vitamin D deficiency is widespread worldwide, and it has been linked to an increased risk of depression. In this article, we have discussed different hypotheses that explain the role of vitamin D in gene expression and its effects on neurotransmitters and different brain functions. We have reviewed literature that shows us that Vitamin D deficiency is a risk factor for depression and explored studies that show us the effects of using or supplementing Vitamin D in preventing depression among various populations.

Introduction And Background

Major depressive disorder (MDD) is a psychiatric illness marked by various symptoms that can harm one’s quality of life [1]. The earliest recorded reports of what is now considered depression were seen in the second millennium B.C.E in Mesopotamia, where depression was considered a spiritual affliction rather than a mental disorder [2]. During the 1970s, physicians in the United States coined the term major depressive disorder [3]. In 1980, it officially became a part of the Diagnostic and Statistical Manual of Mental Disorders-III (DSM) [3]. In 2008, WHO ranked MDD as the third cause of burden of disease and has estimated that by 2030 this disorder will rank first [4]. MDD is two times more prevalent in women than men [5]. People with comorbid psychiatric disorders such as social anxiety and panic disorders or substance use have a higher risk of suicide when diagnosed with MDD [6]. Genetic and environmental factors contribute to the etiology of depression, and some studies report that genetic factors mainly play a role in early-onset depression [7]. In the elderly, strokes, seizure disorders, neurodegenerative diseases, and chronic pain have been implicated with greater risk for developing depression [7]. Other environmental factors such as financial problems, traumatic experiences, death of a loved one, conflicts, and lack of social support are other examples that could trigger depression in an individual [7]. The underlying pathophysiology has not been clearly understood; however, earlier evidence shows that there are abnormalities in neurotransmitters like serotonin (5-HT), norepinephrine (NE), dopamine (DA), glutamate, and brain derived neurotrophic factor (BDNF) [7]. The multifactorial reasons contributing to depression can cause modifications in neuroendocrine and behavioral reactions, which can cause functional and anatomical alterations such as enhanced hyperintensities in subcortical areas and decreased anterior brain metabolism on the left side, respectively [6].

The following is a list of the DSM-5’s nine symptoms (Table 1) [7]. To make a clinical diagnosis, five symptoms out of the nine must be present (one of which should be a sad mood or anhedonia):

How to cite this article

Saji Parel N, Krishna P, Gupta A, et al. (April 21, 2022) Depression and Vitamin D: A Peculiar Relationship. Cureus 14(4): e24363. DOI 10.7759/cureus.24363
| Sl. no. | DSM-5 Criteria               |
|--------|------------------------------|
| 1.     | Feeling sad/low              |
| 2.     | Anhedonia                   |
| 3.     | Thoughts of unworthiness/guilt |
| 4.     | Changes in energy/fatigue   |
| 5.     | Psychomotor retardation or agitation |
| 6.     | Difficulty concentrating    |
| 7.     | Changes in appetite/weight  |
| 8.     | Thoughts of suicide/death   |
| 9.     | Difficulty sleeping         |

### TABLE 1: Clinical features of depression

| Types of treatment | Mechanisms |
|--------------------|------------|
| Lifestyle Modifications | Improving quality of sleep, exercise, healthy eating, meditation, stress management, avoiding alcohol/drug use |
| Classes of Medications | SSRI-inhibit reuptake of 5HT by binding to SERT; SNRI-inhibit reuptake of both serotonin and NE by binding to SERT and NET and weakly inhibits dopamine reuptake; TCA-inhibit reuptake of both 5HT and NE by binding to SERT and NET, antihistamine & anticholinergic; MAOI inhibits the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and increasing their availability; SDAMs- partial agonist at 5-HT1A and D2 receptors and an inhibitor at 5-HT2A and NE alpha type 1B and type 2C receptors, with similar potencies; Atypicals - dopamine reuptake inhibitor, 5HT receptor modulator, inhibits alpha two receptors |
| Psychotherapy: CBT, Interpersonal and psychodynamic | It aids in the recognition and modification of negative thoughts and behaviours. |
| ECT | A seizure is triggered by electrical stimulation when used a few times a week for a short time and eliminates depression symptoms for a prolonged time. |

Depression can be managed by different treatment approaches, which include lifestyle modification, pharmacological (such as selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, serotonin-dopamine activity modulators (SDAMs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs)) [8-13], interventional and psychotherapeutic approaches (such as cognitive behavioral therapy) [6], and combining pharmacological and psychotherapeutic approaches have been proven to be more effective in treatment [14-16]. For severe major depression, electroconvulsive therapy has been more effective than any other therapeutic option [17]. The various treatment approaches to depression are summarized in Table 2.

### TABLE 2: Summary of various approaches to management of depression

SSRI- selective serotonin re-uptake inhibitor, 5HT- serotonin, SERT- serotonin transporter, NE- norepinephrine, SNRI- serotonin norepinephrine reuptake inhibitor, NET- norepinephrine transporter, TCA- tricyclic antidepressants, MAOI- monoamine oxidase inhibitor, SDAM- serotonin dopamine activity modulator, 5HT1A- serotonin type 1A receptor, D2- dopamine type 2 receptor, 5HT2A-serotonin type 2A receptor, CBT- cognitive behavioral therapy, ECT- electroconvulsive therapy

Hypovitaminosis can lead to various conditions, some of which affect mental health [18]. An increasing number of studies link depression with vitamin D deficiency [19]. Since it is theorized that vitamin D plays a
role in gene expression, it regulates the level of 5-HT, DA, and NE receptors in the brain, and low vitamin D levels result in a decrease of these neurotransmitters, which leads to depression [20-23]. This article aims to discuss the role and association of vitamin D in the pathophysiology and management of depression, highlight the impact of vitamin D deficiency and depression in different population groups, and look into the possibility of using vitamin D as an adjunct to antidepressants for a better prognosis.

**Review**

Vitamin D, a fat-soluble vitamin, can be obtained from various sources, including sun exposure, regular dietary intake, and dietary pills [24]. Ultraviolet (UV) B radiation from sunlight enters the skin and transforms 7-dehydrocholesterol to previtamin D3, quickly transforming to vitamin D3 [25]. UV light irradiation produces vitamin D2 from yeast, while vitamin D3 is made by UV irradiation of 7-dehydrocholesterol from lanolin [24]. Vitamin D that is absorbed from the skin and dietary intake is converted in the liver to 25-hydroxyvitamin D (25(OH)D), which can be used to assess a patient’s vitamin D level [25-28]. The kidneys then convert 25(OH)D by the enzyme 25(OH)D-1α-hydroxylase (CYP27B1) to its active form, 1,25-dihydroxy vitamin D [25-28]. It subsequently binds to vitamin D receptors in target organs to control gene transcription and cell membrane structures to conduct different non-genomic responses [29]. Vitamin D receptors are seen in almost every tissue and cell in the body [30,31]. In the brain, it can be found primarily on the hippocampus, prefrontal cortex, hypothalamus, cingulate gyrus, substantia nigra, and thalamus [30,31]. This is important because many of those brain areas have been linked to depression’s physiology [32]. According to increasing research, vitamin D is a neuroactive steroid that plays a critical role in the expression of neurotransmitters with its regulation and neuroimmunomodulation, antioxidant production, and various neurotrophic factors, making it biochemically plausible that vitamin D is associated with depressive symptoms [33]. Although the mechanism by which vitamin D works in the body is unknown, a few hypotheses show us an association between these two [33].

According to the neurotrophic hypothesis, immunohistochemical research has discovered vitamin D receptors (VDRs) in the central nervous system (CNS), providing a solid indication that vitamin D plays a significant role in brain functions [33]. VDRs are found all over the brain, including the hippocampus, which plays a role in controlling memory and emotional function [33]. Because the hippocampus is vital in the causes of depression, discovering VDR within has encouraged many researchers to investigate the effects of vitamin D on hippocampal shape and function in animals [34]. Numerous investigations using in vitro culturing of hippocampal cells and in vivo experiments on the brains of adult mice have revealed that vitamin D deficiency can alter the shape or function of the hippocampal development [35]. Croll et al. conducted a cross-sectional analysis on 2,176 people in the Netherlands (from 2006 to 2009), which showed that those with vitamin D deficiency (serum concentration 30 nmol/L) had decreased brain tissue and hippocampal volume, as seen in their brain magnetic resonance imaging (MRI) [35].

Numerous studies have demonstrated that vitamin D is a potent regulator of the production of neurotrophic substances, such as BDNF, a neurotrophin (NT)-3, and nerve growth factor (NGF) [33]. Neurotrophic factors are necessary for neuron survival, development, and migration, in which they drive their physiological function by combining with their corresponding tropomyosin-related kinase (Trk) receptors, including BDNF/TrkB, NT-3/TrkC, NGF/TrkA, as well as the common p75 neurotrophin receptor (p75NTR) [36]. Various research has shown that 1,25(OH)2D can enhance the production of BDNF, NGF, and NT-3 and downregulate NT-4 in the astrocytes of the brain, indicating that vitamin D plays a role in neuronal survival and differentiation during the development [37,38]. In the adult hippocampus, BDNF is critical for the long-term viability, specialization, and performance of new neurons [33]. NT-3 and NT-4 are necessary for the survival of growing neurons and for the differentiation and proliferation of precursor cells, thereby directly or indirectly affecting the cause of depression [33]. As a result, vitamin D can influence neurotrophic agents, whose aberrant performance has been linked to various psychiatric disorders [33]. According to the classic monoamine neurotransmission hypothesis, the deficiency of monoamines such as 5-HT, DA, and NE can cause depression [33].

On the other hand, vitamin D deficiency may interfere with the synthesis of 5-HT, resulting in the aberrant development of serotonergic and brain neurons [33]. 5-HT also functions on the hippocampus, where the production of new neurons and synaptic plasticity have been linked to the onset and treatment of depression [33]. The VDR is found in dopaminergic neurons in the substantia nigra, prefrontal cortex, and hippocampus of humans and rats, all of which are linked to depression [39]. Vitamin D deficiency can cause a delay in DA cell differentiation because of its effects on VDR expression in the substantia nigra, which can lead to DA-mediated behavioral deficits [40]. It also suggests that vitamin D deficiency can affect dopaminergic neuron development and have severe effects on the evolution of depression [33]. Hence, vitamin D directly or indirectly influences the levels of monoamines in the body and is involved in the pathogenesis of depression [33].

**Literature review of the association between vitamin D and depression**

*In Adults and Elderly*

It is crucial to note that vitamin D deficiency has been seen in a range of populations, including children,
adolescents, adults, and the elderly, irrespective of race, ethnicity, or nation [41-43]. Depression is related to cardiovascular (CV) events, and it has been indicated that vitamin D deficiency may be linked to depression and a significant contributor to a higher risk of CV events [44]. May et al. conducted a nine-year cohort study in Utah, USA, which found that lower vitamin D levels were significantly associated with depression among 7558 patients aged 50 years or older with cardiovascular disease [44]. In the elderly, vitamin D deficiency is a risk factor for developing depression [45]. Milaneschi et al. conducted a population-based cohort study in Tuscany, Italy, to explore the connection between 25(OH)D levels and depression symptoms in 425 men and 531 women aged 65 years and older over six years [45]. Men (hazard ratio = 1.6; 95% confidence interval (CI) = 0.9–2.8; P = 0.1) and women (hazard ratio = 2.0; 95% confidence interval (CI) = 1.2–3.2; P = 0.005) with a serum 25(OH)D of less than 50 nmol/L had a higher risk of depression, with the magnitude of the potential association being greater in women than in men [45]. The study mentioned above is similar to a cohort study by Chan et al. in Hong Kong, China, which included 939 males aged 65 and up [46]. The results demonstrated that there is an inverse relationship between serum 25(OH)D and depression (odds ratio = 0.46, 95% confidence interval (CI): 0.22–0.98, P = 0.004) in 629 males after a four-year follow-up period [46]. A non-interventional prospective cohort study done by Lee et al. in Europe also concluded an inverse relationship between depression and 25(OH)D levels [47]. Its results showed decreased levels of 25(OH)D were associated with increased BDI-II score (p = 0.004) [47]. Late-life depression can also be linked to vitamin D deficiency [48]. According to Stewart and Hirani’s data analyzed among 2070 people in England 65 years or older showed that depressive symptoms were related to vitamin D deficiency when the 25(OH)D levels were lower than 10ng/mL [48].

In Women and During Pregnancy

Vitamin D deficiency has traditionally been known to harm the bones, such as having osteopenia and osteoporosis due to having low bone mineral density (BMD) [49]. Premenopausal women with depression and older African-American adults with Vitamin D deficiency are more likely to have low BMD [49,50]. Depression is the most common mood illness in pregnancy and postpartum due to significant hormonal, physical, and social changes [51]. In developing countries, the occurrence of depression in pregnancy has been estimated to be as high as 20%, while it was between 10% and 15% in developed countries [52]. Moreover, 20–40 percent of women globally suffer from postpartum depression (PPD), which is defined as a nonpsychotic depressive disorder that occurs within a year following childbirth [53,54]. Lower levels of Vitamin D in pregnant women have resulted in increased depressive symptoms [55]. A study by Cassidy-Bushrow et al. in Detroit that assessed vitamin D levels and depression screening in 178 pregnant African American women showed that there was a strong inverse correlation between log (25-OHD) and Center for Epidemiologic Studies-Depression scale (CES-D) score of >16 [54]. The chances of CES-D >16 decreased by 46% for every 1-unit rise in log (25-OHD) (equivalent to 2.72 ng/mL increase in 25-(OH)D) (OR=0.54, 95% CI. 0.29–0.99, p=0.046) [55]. The above study results are comparable to a cohort study done in Amsterdam by Brandenbarg et al. among 4101 pregnant women whose vitamin D levels were assessed at 13 weeks gestation [56]. Screening for depression was done using the CES-D scale (score ≥ 16) at 16 weeks gestation, and the study concluded that early-pregnancy vitamin D deficiency was linked to increased depression symptoms during pregnancy [56]. Gur et al. conducted a cohort study in Turkey that included 179 pregnant women between 24 and 28 weeks of pregnancy [57]. Depression was screened for using The Edinburgh Postnatal Depression Scale (EPDS), and vitamin D levels were assessed [57]. The above study is similar to a cohort study done by Fu et al. in Beijing, China, where serum vitamin D levels were assessed 24–48 hours postpartum, and EPDS was used to screen for depression (score >12) three months postpartum [58]. The study also concluded that lower 25(OH)D levels were linked to PPD [58]. The above-mentioned studies [44-49, 54, 56-58] are summarized in Table 3 below:
| References            | Type of study | Sample size | Population                  | Location     | Diagnostic criteria                                                                 | Conclusion                                                                 |
|-----------------------|---------------|-------------|-----------------------------|--------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| May et al. (2010)     | COHORT        | 7358        | Adults aged 50 years or older with CVD | UTAH, USA    | Depression- ICD-9 Vit D- >50, 31-50,16-30 and or = 15                                 | Vit D levels were significantly associated with depression .                  |
| Milaneschi et al. (2010) | COHORT       | 954         | Age ≥65 years                | TUSCANY, ITALY | Depression- CES-D Vit D- <50nmol/L                                                    | VDD is a risk factor for the development of depression.                      |
| Chan et al. (2011)    | COHORT        | 939         | Men aged ≥65 years           | HONG KONG, CHINA | NA                                                                                   | Inverse relationship exists between serum 25(OH)D and depression             |
| Lee et al. (2011)     | COHORT        | 3369        | Men aged 49-71 years         | EUROPE       | Depression- BDI-II Vit D and PTH levels by radioimmunoassay                           | Inverse relationship between depression and 25(OH)D levels                   |
| Stewart et al. (2010) | NA            | 2070        | Adults ≥ 65 years            | ENGLAND      | Depression- GDS Vit D levels                                                         | Late-life depression is linked to VDD                                       |
| Cassidy-Bushrow et al. (2012) | NA | 178         | African-American Pregnant women | DETROIT, USA  | Depression- CES-D Vit D levels                                                      | Increased depressive symptoms were seen in pregnant women with lower Vit D levels |
| Brandenbarg et al. (2012) | COHORT    | 4101        | Pregnant women               | AMSTERDAM    | Depression- CES-D Vit D levels                                                      | Increased depressive symptoms were seen in pregnant women with lower Vit D levels |
| Gur et al. (2014)     | COHORT        | 179         | Pregnant women               | TURKEY       | Depression- EPDS Vit D levels                                                       | VDD during pregnancy may have a role in the onset of PPD                     |
| Fu et al. (2014)      | COHORT        | 213         | Pregnant women               | BEIJING, CHINA | Depression- EPDS Vit D levels                                                       | PPD associated with low vit D levels                                        |

### TABLE 3: Summary of included studies linking depression and vitamin D deficiency

BDI-II - Beck Depression Inventory-II, Vit D- Vitamin D, PTH- Parathyroid hormone, 25(OH)D-25 - Hydroxyvitamin D, ICD-9 - International Classification of Diseases, Ninth Revision, GDS- Geriatric Depression Scale, VDD- Vitamin D Deficiency, CES-D - Center for Epidemiological Studies-Depression Scale, EPDS- Edinburgh Postnatal Depression Scale, PPD- Postpartum depression, NA- not available

---

**Treatment and management**

Even though studies evaluating the relationship between vitamin D and mental well-being use a variety of study groups, outcomes, and behavioral assessments, the findings are consistent, suggesting that vitamin D blood levels or supplementation may positively influence mental health [59]. Based on these observations, it is possible to conclude that vitamin D is essential for mental health, regardless of the examined group or effect linked with mental health [59].

**In Adolescents**

Högberg et al. concluded a positive association between vitamin D supplementation and improvement of depressive symptoms in depressed adolescents with low serum 25(OH)D in Sweden [60]. Their mean serum 25(OH)D was 41 nmol/L at baseline and 91 nmol/L (p < 0.001) after supplementation, with a significant amelioration of depression according to the Mood and Feelings Questionnaire (MFQ-S) (p < 0.05) [60]. This study is similar to the interventional study done in Iran by Bahrami et al., where for nine weeks, 940 adolescent girls were given vitamin D3 at a level of 50,000 IU/week, and a substantial reduction in depression scores (8 (4-16) vs 7 (2-14); p =.001) after nine weeks of vitamin D treatment along with a dramatic increase in median serum 25(OH)D levels (6.7 ng/mL at baseline vs 35.5 ng/mL after the intervention; p >.001) was noticed [61]. Their results indicate that vitamin D supplementation benefits adolescents with depressive symptoms and low levels of vitamin D at baseline [60,61].

**In Adults**

Sepehrmanes et al. randomly assigned adults diagnosed with MDD to receive 50,000 IU of Vitamin D (n = 20) or placebo (n = 20) for eight weeks (Table 4) [62]. Improvements in serum 25(OH)D concentrations were considerably greater in the vitamin D group (+20.4 μg/L) than compared to the placebo group (-0.9 μg/L, P <
after eight weeks of intervention. Also, there was a trend toward a higher decline in the BDI scores in the vitamin D group than in the placebo group [62]. This study can be compared to a cross-sectional and interventional analysis done by Stokes et al. [63], in which 77 depressed patients with chronic liver disease were given 20,000 IUs of Vitamin D for six months (Table 4). In the study’s conclusion, it was seen that the severity of depression was inversely related to vitamin D serum levels ($\beta = -0.483, P = 0.004$). BDI-II scores also improved significantly from baseline after three and six months ($P = 0.003$ and $P = 0.004$, respectively), and vitamin D’s antidepressant impact was found to be more prevalent in women in subgroup studies [65].

**In Pregnancy**

According to Vaziri et al., vitamin D supplementation during pregnancy can help decrease perinatal depression (Table 4) [64]. One hundred sixty-nine pregnant women received 2000 IU of vitamin D3 or a placebo every day from 26 to 28 weeks of pregnancy until delivery. Although both groups had comparable baseline 25(OH)D concentrations, the vitamin D group had a considerably greater 25(OH)D concentration than the control group at childbirth ($p = 0.001$). There was no link between 25(OH)D concentration and depression score at the start ($r = 0.15, p = 0.09$). While the vitamin D group had a bigger reduction in depression scores than the control group at 38-40 weeks of pregnancy ($p = 0.01$), the vitamin D group also showed a greater reduction in depression scores at four and eight weeks after birth ($p = 0.001$) [64].

**In Conjunction With Other Antidepressants**

Vitamin D combined with other antidepressants could be beneficial in managing depression. Khoraminya et al. randomized adults with depression into two groups to receive a combination of 1500 IU Vit D3 and fluoxetine or fluoxetine alone (Table 4) [65]. At the end of eight weeks, the study showed that vitamin D and fluoxetine combination was more effective than fluoxetine alone in managing depression. Mozaffari-Khosrav et al. studied randomized patients (diagnosed with depression and had vitamin D deficiency) to verify if correcting vitamin D deficiency alleviates depressive symptoms (Table 4) [66]. One hundred twenty patients received an intramuscular injection of 150,000 IU vitamin D (n = 40) or 300,000 IU vitamin D (n=40) or nothing (n=40). After three months, it was found that there was a significant difference in mean BDI II test score ($P = 0.003$) between the group that received 300,000 IU vitamin D injection and the group that received nothing. The study’s findings demonstrated that correcting vitamin D deficiency alleviates depressive symptoms and that a single injectable dose of 300,000 IU of vitamin D was both safe and beneficial compared to a 150,000-IU dose [66]. Therefore, management of depression with vitamin D supplementation can significantly impact, as vitamin D is both an effective antidepressant and a cost-efficient option [33]. While those with severely low levels of serum vitamin D would benefit from supplements, people with adequate amounts of serum vitamin D levels will not benefit from it and would not notice a reduction in depression [33].
| References                        | Type of study | Sample size | Population                                | Location     | Duration | Intervention                                      | Diagnostic criteria                        | Conclusion                                                                 |
|----------------------------------|---------------|-------------|-------------------------------------------|--------------|----------|-------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------|
| Sepehrmanesh et al. [62] 2015    | RCT           | 40          | Aged between 18-65 years, diagnosed with MDD | NA           | 8 weeks  | 50,000 IU vit D per week (n = 20) or placebo (n = 20) | BDI Vit D level Glucose, CRP Lipid profile | improvement of BDI score after Vit D supplementation                          |
| Stokes et al. [63] 2016          | Cross sectional & Interventional | 188        | Chronic liver disease patients with depression | GERMANY      | 6 months | 20,000 IU per week                              | BDI-II Vit D level                        | BDI-II scores improved significantly from baseline after three and six months & Vit D's antidepressant impact was found to be more prevalent in women in subgroup studies |
| Vaziri et al. [64] 2016           | RCT           | 169         | Pregnant women ≥18 years, GA 26-28 week    | SHIRAZ, IRAN |          | 2000 IU Vit D3 daily from 26 to 28 weeks of gestation until delivery or placebo | EPDS Vit D level                          | Use of 2000 IU vitamin D3 per day throughout late pregnancy was found to be beneficial in decreasing perinatal depression |
| Khoraminya et al. [65] 2013      | RCT           | 42          | Aged between 18-65 years, diagnosed with MDD | TEHRAN       | 8 weeks  | 1500 IU Vit D3 + 20 mg fluoxetine or fluoxetine alone | HDRS BDI Vit D level                      | Vit D and fluoxetine combo is more effective than fluoxetine alone            |
| Mozaffari-Khosrav et al. [66] 2013 | RCT         | 120         | Depressed patients with VDD                | YAZD, IRAN   | 3 months | 1 single injection of 150,000 IU or 1 single injection of 300,000 IU of Vit D or none | BDI-II Vit D level Ca, P, PTH             | Correcting vitamin D deficiency alleviates depressive symptoms, and a single injectable dose of 300,000 IU of vit D was both safe and beneficial when compared to a 150,000-IU dose |

**TABLE 4: Summary of included studies showing the association between vitamin D supplementation and depression**

RCT- randomised controlled trial, GA- gestational age, MDD - major depressive disorder, VDD- vitamin D deficiency, IU- International units, Vit D- Vitamin D, BDI- Beck depression inventory, EPDS- Edinburgh Postnatal Depression Scale, CRP- C-reactive protein, Ca- Calcium, P- phosphate, PTH- Parathyroid hormone, HDRS- Hamilton Depression Rating Scale, NA- not available

**Limitations**

The causes of depression are multifactorial and include multiple genetic, environmental, and social factors, and this article has solely focused on the causes and effects of vitamin D deficiency. Also, this study does not address the effect of vitamin D deficiency in the paediatric population.

**Conclusions**

In this article, we discussed depression and determined vitamin D's relationship with depression in its pathogenesis and management across various population groups. We notably discussed how vitamin D deficiency could impact brain structure, function, and effects among adults. The inverse correlation between depression and serum vitamin D levels and the therapeutic benefits of supplementing vitamin D levels highlights the clinical implication of this article. Depressed patients require a tailored approach to treatment, and vitamin D levels should be evaluated as part of their routine assessment. Furthermore, we feel that additional studies need to be conducted in exploring vitamin D's relationship with depression management and universally defining low vitamin D status, thereby formally correlating the two to form an integrated approach to managing depression.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Salik I, Marwaha R: Electroconvulsive therapy. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2022 Jan-
2. Reynolds EH, Wilson JV: Depression and anxiety in Babylon. J R Soc Med. 2015, 108:478-81. doi: 10.1177/0141076015546262
3. The history of depression: accounts, treatments, and beliefs through the ages. (2020). Accessed: April 18, 2022: https://www.verywellmind.com/who-discovered-depression-1066770
4. Malhi GS, Mann JJ: Depression. Lancet. 2018, 392:2299-312. 10.1016/S0140-6736(18)31948-2
5. Pedersen CB, Mors O, Bertelsen A, et al.: A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014, 71:573-81. 10.1001/jamapsychiatry.2014.16
6. Bains N, Ahijadiad S: Major depressive disorder. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2022 Jan-
7. Chand SP, Arif H: Depression. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2022 Jan-
8. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM: Psychological autopsy studies of suicide: a systematic review. Psychol Med. 2005, 35:395-405. 10.1017/S0033291702006945
9. Li Z, Page A, Martin G, Taylor R: Attributable risk of psychiatric and socio-economic factors for suicide from individual-level, population-based studies: a systematic review. Soc Sci Med. 2011, 72:608-16. 10.1016/j.socscimed.2010.11.008
10. Ressler KJ, Mayberg HS: Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007, 10:1116-24. 10.1038/nmn1944
11. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Smit JH, Poswer F: Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006, 49:837-45. 10.1007/s00125-006-0159-x
12. Berton O, Nestler EJ: New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006, 7:137-51. 10.1038/nrn1846
13. Krishnan V, Nestler EJ: The molecular neurobiology of depression. Nature. 2008, 455:894-902. 10.1038/nature07455
14. Kroenke K, Spitzer RL, Williams JB: The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003, 41:1284-92. 10.1097/01.MLR.0000080935.87866.3C
15. Cuijpers P, Dekker J, Hollon SD, Andersson G: Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009, 70:1219-29. 10.4088/JCP.09r05021
16. Cuijpers P, Van Straten A, Warmerdam L, Andersson G: Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety. 2009, 26:279-88. 10.1002-da.20519
17. Pagnin D, de Queiroz V, Pini S, Cassano GB: Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004, 20:15-20. 10.1097/01.ject.0000093548.78664.3C
18. Rao TS, Asha MR, Ramesh BN, Rao KS: Pharmacological profile, preclinical and clinical evaluation of a novel antidepresant. J Pharmacol. 2004, 20:13-20.
19. Pagnin D, de Queiroz V, Pini S, Cassano GB: Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004, 20:15-20. 10.1097/01.ject.0000093548.78664.3C
20. Patrick RP, Ames BN: Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEBJ J. 2015, 29:2207-22. 10.1096/f.14.268742
21. Delgado PL: Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000, 61 Suppl 6:7-11.
22. Cui X, Pertoit R, Liu P, Eyles DW: Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator. Neuroscience. 2015, 304:90-100. 10.1016/j.neuroscience.2015.07.048
23. Daubner SC, Le T, Wang S: Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 2011, 508:1-12. 10.1016/j.abb.2010.12.017
24. Holick MF: Vitamin D deficiency. N Engl J Med. 2007, 357:266-81. 10.1056/NEJMra070553
25. Holick MF: Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006, 116:2062-72. 10.1172/JCI29449
26. Bikle DD: Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014, 21:319-29. 10.1016/j.chembior.2013.12.016
27. Bouillon R, Degroot L, Jameson JL, Burger HG: Vitamin D: photosynthesis, metabolism, and action to clinical applications. Endocrinology, 3rd Edition. Degroot L, Jameson JL, Burger HG (ed): WB Saunders, Philadelphia; 2001. 1009-28.
28. DeLaca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004, 80:1689S-96S. 10.1093/ajcn/80.6.1689S
29. Parker GB, Broitche H, Graham RK: Vitamin D and depression. J Affect Disord. 2017, 208:56-61. 10.1016/j.jad.2016.08.082
30. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ: Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Clin Endocrinol Metab. 2005, 92:21-30. 10.1016/j.jcem.2004.08.006
60 Högberg G, Gustafsson SA, Hällström T, Gustafsson T, Klawitter B, Petersson M: and status on mental health in children: a systematic review
59 Głąbska D, Kołota A, Lachowicz K, Skolmowska D, Stachoń M, Guzek D: Obstet Gynecol Reprod Biol. 2014, 179:110-6.
58 Gur EB, Gokduman A, Turan GA, et al.: cohort postpartum depression: a case-control study 10.1089/jwh.2012.3528
57 Cassidy-Bushrow AE, Peters RM, Johnson DA, Li J, Rao DS: as aspects in developed and developing countries
56 Pereira PK, Lovisi GM, Lima LA, et al.: Obstet. 2018, 298:1045-59. and postpartum depression: a systematic review and meta-analysis of longitudinal studies 10.1007/s00404-018-4902-6
55 El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Elier P.: Relevance of norepinephrine–dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010, 16:e1-17. 10.1111/j.1755-9949.2010.01416.x
54 Wewerinke A, Honig A, Heres MH, Wennink JM: 10.1016/j.ahj.2010.03.017
53 Binkley N, Krueger D, Cowgill CS, et al.: 10.1016/j.ajge.2015.03.009
52 Wilkins CH, Birge SJ, Sheline YI, Morris JC: 10.1016/j.ajh.2010.03.017
51 Milaneschi Y, Shardell M, Corsi AM, Vazzana R, Bandinelli S, Guralnik JM, Ferrucci L: 10.1016/j.annepidem.2007.12.001
50 Wang J, Liu N, Sun W, Chen D, Zhao J, Zhang W: Ned Tijdschr Geneeskd. 2006, 150:294-8.
49 Greene-Finestone LS, Berger C, de Groh M, et al.: 10.1017/S0007114511003527
48 Wilkins CH, Birge SJ, Sheline YI, Morris JC: 10.1016/j.ajh.2010.03.009
47 Eyles DW, Burne TH, McGrath JJ: Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013, 34:47-64. 10.1016/j.yfrne.2012.07.001
46 Drevets WC, Price JL, Furey ML: Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008, 213:95-118. 10.1007/s00429-008-0189-x
45 Gerg C, Shaikh AS, Han W, Chen D, Guo Y, Jiang P: Vitamin D and depression: mechanisms, determination and application. Asia Pac J Clin Nutr. 2019, 28:689-94. 10.6133/apjcn.201912_28(4).0005
44 Holick MF: Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009, 19:73-8. 10.1016/j.annepidem.2007.12.001
43 Ceoli PH, Boerma M, Vernooy MW, van de Rest O, Zibikens MC, Ikram MA, Voortman T.: Associations of vitamin D deficiency with MRI markers of brain health in a community sample. Clin Nutr. 2021, 40:72-8. 10.1016/j.clnu.2020.04.027
42 Wysokinski A: Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia. Nord J Psychiatry. 2016, 70:267-71. 10.3109/08039488.2015.1087592
41 Bigilc A, Toker A, Işık Ü, Kılınç İ: Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurophin-3 levels in children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017, 26:355-65. 10.1007/s00787-016-0898-2
40 Jaumotte JD, Wyrostek SL, Zigmond MJ: Protection of cultured dopamine neurons from MPP+(+) requires a combination of neurotrophic factors. Eur J Neurosci. 2016, 44:1691-9. 10.1111/ejn.13252
39 El Massari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Elier P: Relevance of norepinephrine–dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010, 16:e1-17. 10.1111/j.1755-9949.2010.01416.x
38 Gonzalez-Gross M, Valtuena I, Breidenassel C, et al.: Vitamin D status among adolescents in Europe: the Healthy Lifestyle in Europe by Nutrition in Adolescence study. Br J Nutr. 2012, 107:755-64. 10.1017/S0007114511003527
37 Greene-Finestone LS, Berger C, de Groh M, et al.: 25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int. 2011, 22:1589-99. 10.1002/htj.20149
36 Binkley N, Krueger D, Cowgill CS, et al.: 10.1002/htj.20149
35 Lee DM, Tajar A, O'Neill TW, et al.: Lower vitamin D levels are associated with depression among community-dwelling European men. J Psychosom Med. 2011, 25:1520-8. 10.1016/j.jpsychmol.2011.03.079
34 Stewart R, Hirani V: 10.1007/s00404-018-4902-6
33 Chan R, Chan D, Woo J, Ohlschon C, Mellström D, Kwok T, Leung P: Association between serum 25-hydroxyvitamin D and psychological health in older Chinese men in a cohort study. J Affect Disord. 2011, 130:251-9. 10.1016/j.jad.2010.02.029
32 Lee DM, Tajar A, O'Neill TW, et al.: Lower vitamin D levels are associated with depression among community-dwelling European men. J Psychosom Med. 2011, 25:1520-8. 10.1016/j.jpsychmol.2011.03.079
31 Eyles DW, Burne TH, McGrath JJ: Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013, 34:47-64. 10.1016/j.yfrne.2012.07.001
case-series were low in vitamin D and depression was ameliorated by vitamin D supplementation. Acta Paediatr. 2012, 101:779-83. 10.1111/j.1651-2227.2012.02655.x

61. Bahrami A, Mazloum SR, Maghsoudi S, et al.: High dose vitamin D supplementation is associated with a reduction in depression score among adolescent girls: a nine-week follow-up study. J Diet Suppl. 2018, 15:173-82. 10.1080/19390211.2017.1354736

62. Sepehrmanesh Z, Kolahdooz F, Abedi F, Mazrooi N, Assarian A, Asemi Z, Esmaillzadeh A: Vitamin D supplementation affects the Beck depression inventory, insulin resistance, and biomarkers of oxidative stress in patients with major depressive disorder: a randomized, controlled clinical trial. J Nutr. 2016, 146:245-8. 10.3945/jn.115.128883

63. Stokes CS, Grünhage F, Baus C, Vulmer DA, Wagenpfeil S, Riemenschneider M, Lammert F: Vitamin D supplementation reduces depressive symptoms in patients with chronic liver disease. Clin Nutr. 2016, 35:950-7. 10.1016/j.clnu.2015.07.004

64. Vaziri F, Nasiri S, Tavana Z, Dabbaghmanesh MH, Sharif F, Jafari P: A randomized controlled trial of vitamin D supplementation on perinatal depression: in Iranian pregnant mothers. BMC Pregnancy Childbirth. 2016, 16:239. 10.1186/s12884-016-1024-7

65. Khoraminya N, Tehrani-Doost M, Jazayeri S, Hosseini A, Djazayery A: Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder. Aust N Z J Psychiatry. 2015, 47:271-5. 10.1177/0004867414526502

66. Mozaffari-Khosravi H, Nabizade L, Yassini-Ardakani SM, Hadinedoushan H, Barzegar K: The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency: a randomized clinical trial. J Clin Psychopharmacol. 2015, 35:378-85. 10.1097/JCP.000000000000019a